(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites

The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE. A re...

Descripción completa

Detalles Bibliográficos
Autores principales: Thapa, Pradeep, Parghane, Rahul, Basu, Sandip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460307/
https://www.ncbi.nlm.nih.gov/pubmed/28670182
http://dx.doi.org/10.4103/1450-1147.207283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460307/
https://www.ncbi.nlm.nih.gov/pubmed/28670182
http://dx.doi.org/10.4103/1450-1147.207283

Ejemplares similares